News

Prophylactic antibiotic combination reduces incidence of infection following ASCT

Results from a retrospective study have shown that prophylactic treatment with doxycycline and ciprofloxacin reduces the incidence of infection in myeloma patients following an autologous stem cell transplant (ASCT), when compared to treatment with ciprofloxacin alone. Published in Supportive Cancer Care, the results show that 53% of patients receiving ciprofloxacin alone developed neutropenic fever compared…

Details

EMA issues second negative recommendation for plitidepsin combination

The European Medicines Agency (EMA) has issued a second negative recommendation for plitidepsin (Aplidin®) in combination with dexamethasone for the treatment of relapsed and refractory myeloma. The application to authorise this treatment combination was re-examined by the EMA after receiving an initial negative recommendation in December 2017. This decision was based upon data from the…

Details

Results from Phase II vaccine trial announced

The biopharmaceutical company, SELLAS Life Sciences, has presented results from its Phase II galinpepimut-S trial at the 44th Annual European Society for Blood and Marrow Transplantation (EBMT) meeting. Galinpepimut-S is a peptide vaccine that targets WT1, a protein expressed on the surface of myeloma cells, and stimulates a CD4+ and CD8+ immune response. The trial…

Details

Ixazomib combination demonstrates efficacy in relapsed and refractory myeloma patients

Results from a Phase II study, recently published in Leukaemia, show that the oral combination of ixazomib (Ninlaro®), pomalidomide (Imnovid®) and dexamethasone is effective in relapsed and refractory myeloma patients. All patients in this study were refractory to lenalidomide (Revlimid®). 48% of patients who received the recommended dose of ixazomib (4mg) achieved a partial response or…

Details

Pomalidomide combination shows efficacy in relapsed and refractory myeloma patients with renal impairment

Published in the Journal of Clinical Oncology, results from the Phase II trial, MM-013 show that pomalidomide (Imnovid®) in combination with low-dose dexamethasone is effective in relapsed and refractory patients with renal impairment. There were 3 cohorts in this trial; patients with moderate renal impairment (A), severe renal impairment (B) and severe impairment requiring haemodialysis…

Details

EMA recommends expanded denosumab indication for myeloma

Amgen has announced that the European Medicine’s Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation to expand the existing licence for denosumab (Xgeva®) to treat skeletal-related events in myeloma patients. This decision is based on the results from a Phase III trial which compared denosumab to zoledronic acid…

Details

Results from Phase III ALCYONE trial published

The results from the Phase III ALCYONE trial have recently been published in The New England Journal of Medicine. The study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone in newly diagnosed myeloma patients, ineligible for a stem cell transplant. The results show that the 18-month progression-free survival…

Details

Phase III pomalidomide trial reaches primary endpoint

Celgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…

Details

Carfilzomib combinations demonstrate overall survival benefit in relapsed and refractory myeloma

Results from the Phase III ASPIRE trial show that carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone has a significant overall survival (OS) benefit in relapsed and refractory myeloma patients. Recently published in the Journal of Clinical Oncology, the results demonstrate that patients receiving carfilzomib, lenalidomide and dexamethasone had a median OS of 48.3…

Details